Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $22.00

Zevra Therapeutics (NASDAQ:ZVRA) had its price objective boosted by Guggenheim from $20.00 to $22.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday. Canaccord Genuity Group dropped their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday. Finally, Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and an average target price of $22.14.

Zevra Therapeutics Trading Up 4.7 %

NASDAQ:ZVRA opened at $8.31 on Thursday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $449.70 million, a PE ratio of -4.22 and a beta of 1.98. The stock’s 50 day moving average price is $7.93 and its 200 day moving average price is $8.16. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The company had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. On average, research analysts anticipate that Zevra Therapeutics will post -1.95 EPS for the current year.

Insider Buying and Selling at Zevra Therapeutics

In related news, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now directly owns 51,361 shares in the company, valued at $403,697.46. The trade was a 17.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the sale, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. This trade represents a 21.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 85,773 shares of company stock valued at $674,176. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics during the fourth quarter valued at $53,000. China Universal Asset Management Co. Ltd. purchased a new position in Zevra Therapeutics in the 4th quarter valued at about $94,000. XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics during the 3rd quarter worth about $94,000. Intech Investment Management LLC purchased a new stake in shares of Zevra Therapeutics during the third quarter worth about $95,000. Finally, Squarepoint Ops LLC raised its position in shares of Zevra Therapeutics by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after buying an additional 4,384 shares during the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.